Gubina N. V., Kupnovytska I. G.

ASSESSMENT OF THE EFFECT OF RESISTIN ON INFLAMMATION AND METABOLIC DISORDERS IN PATIENTS WITH CHRONIC KIDNEY DISEASE RELATED TO OBESITY

---

Show/Download

About the author:

Gubina N. V., Kupnovytska I. G.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Chronic kidney disease (CKD) and obesity are serious public health problems worldwide. Currently, the role of resistin in the pathogenesis of systemic metabolic disorders and the development of associated early stages of CKD remains poorly understood. Aim of the study: research of the level of resistin, its relationship with metabolic and inflammation indicators in patients in the early stages of obesity-related CKD. 300 patients with CKD were examined. The patients were divided into 4 groups: group 1 (70) – patients with stage I CKD with normal body weight, group 2 (72) – patients with stage 2 CKD with normal body weight; group 3 (70) – patients with stage 1 CKD and obesity, group 4 (88) – patients with stage II CKD and obesity. The control group consisted of 30 practically healthy individuals. All patients had their BMI and waist-to-hip ratio (WHR) measured, and their glomerular filtration rate (GFR) was calculated using CRD-EPI formulas based on creatinine, cystatin C, and their combination (CRD-EPIcysC/cr) (ml/ min/1.73 m2). The level of cystatin C (mg/l) in blood serum was determined by immunoenzymatic analysis. The level of resistin (ng/ml) in blood serum, C-reactive protein (μg/ml), and tumour necrosis factor-alpha (TNF-α) (pg/ml) were determined using enzyme-linked immunosorbent assay. The HOMA-IR index was calculated using the formula. In patients with early stages of chronic kidney disease, an additional factor in pathogenesis may be changes in the level of resistin, an adipokine of adipose tissue, the content of which increases as kidney function progresses. These changes in resistin also increase insulin resistance and activate indicators of low-grade inflammation.

Tags:

Bibliography:

1. Timofte D, Dragoș D, Balcangiu-Stroescu AE, Tănăsescu MD, Gabriela Bălan D, Răducu L, et al. Abdominal aortic calcification in predial- ysis patients: Contribution of traditional and uremia-related risk factors. Exp Ther Med. 2020;20(1):97-102. DOI: 10.3892/etm.2020.8607.
2. Silva Junior GB, Bentes AC, Daher EF, Matos SM. Obesity and kidney disease. J Bras Nefrol. 2017;39(1):65-69. DOI: 10.5935/0101-2800.2017 0011.
3.  Perreault L. Obesity in Adults: Prevalence, Screening and Evaluation. Uptodate. 2024. Available from: https://www.uptodate.com/contents/obesity-in-adults-prevalence-screening-and-evaluation.
4.  Nittari G, Scuri S, Petrelli F, Pirillo I, di Luca NM, Grappasonni I. Fighting obesity in children from European World Health Organization member states. Epidemiological data, medical-social aspects, and prevention programs. Clin Ter. 2019;170(3):e223-e230. DOI: 10.7417/CT.2019.2137.
5.  Martínez-Montoro JI, Morales E, Cornejo-Pareja I, Tinahones FJ, Fernández-García JC. Obesity-related glomerulopathy: Current ap- proaches and future perspectives. Obes Rev. 2022;23(7):e13450. DOI: 10.1111/obr.13450.
6. Mascali A, Franzese O, Nisticò S, Campia U, Lauro D, Cardillo C, Di Daniele N, Tesauro M. Obesity and kidney disease: Beyond the hy- perfiltration. Int J Immunopathol Pharmacol. 2016;29(3):354-63. DOI: 10.1177/0394632016 643550.
7. Okabayashi Y, Tsuboi N, Sasaki T, Haruhara K, Kanzaki G, Koike K, et al. Glomerulopathy Associated With Moderate Obesity. Kidney Int Rep. 2016;1(4):250-255. DOI: 10.1016/j.ekir.2016.08.006.
8. Nguyen A, Khafagy R, Gao Y, Meerasa A, Roshandel D, Anvari M, Lin B, et al. Association Between Obesity and Chronic Kidney Disease: Multivariable Mendelian Randomization Analysis and Observational Data From a Bariatric Surgery Cohort. Diabetes. 2023;72(4):496-510. DOI: 10.2337/db22-0696.
9.  Cabandugama PK, Gardner MJ, Sowers JR. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardi- orenal Metabolic Syndrome. Med Clin North Am. 2017;101(1):129-137. DOI: 10.1016/j.mcna.2016.08.009.
10. Miricescu D, Balan DG, Tulin A, Stiru O, Vacaroiu I A, Mihai D A, Popa C C, et al. Impact of adipose tissue in chronic kidney disease devel- opment (Review). Experimental and Therapeutic Medicine. 2021;21(5):539. DOI: https://doi.org/10.3892/etm.2021.9969.
11. Xu W, Zhu Y, Wang S, Liu J, Li H. From Adipose to Ailing Kidneys: The Role of Lipid Metabolism in Obesity-Related Chronic Kidney Dis- ease. Antioxidants (Basel). 2024;13(12):1540. DOI: 10.3390/antiox13121540.
12. Jonas MI, Kurylowicz A, Bartoszewicz Z, Lisik W, Jonas M, Domienik-Karlowicz J, et al. Adiponectin/resistin interplay in serum and in adi- pose tissue of obese and normal-weight individuals. Diabetol Metab Syndr. 2017;9:95. DOI: 10.1186/s13098-017-0293-2.
13. Acquarone E, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: A reappraisal. Mech Ageing Dev. 2019;178:46-63. DOI: 10.1016/j.mad.2019.01.004.
14.  Taouis M, Benomar Y. Is resistin the master link between inflammation and inflammation-related chronic diseases? Mol Cell Endocrinol. 2021;533:111341. DOI: 10.1016/j.mce.2021.111341.
15.  Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143(11):1157-1172. DOI: 10.1161/CIRCULA TIONAHA.120.050686.
16. Tripathi D, Kant S, Pandey S, Ehtesham NZ. Entesham. Resistin in metabolism, inflammation, and disease. The FEBS Journal. 2020;287(15):3141-3149. DOI: https://doi.org/10.1111/febs.15322.
17.  Zhang H, Li X, Kan Y, Yang F, Hou Y, Du Y. Analysis of the correlation between serum resistin and the variability of erythropoietin respon- siveness in patients with chronic kidney disease. Exp Ther Med. 2015;10(5):1925-1930. DOI: https://doi.org/10.3892/etm.2015.2772.
18. Abudalo R, Alqudah A, Qnais E, Athamneh RY, Oqal M, Alnajjar R. Interplay of adiponectin and resistin in type 2 diabetes: Implications for insulin resistance and atherosclerosis. Pharmacia. 2024;71:1-8. DOI: https://doi.org/10.3897/pharmacia.71.e114863.
19. Su KZ, Li YR, Zhang D, Yuan JH, Zhang CS, Liu Y, et al. Relation of Circulating Resistin to Insulin Resistance in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis. Front Physiol. 2019;10:1399. DOI: 10.3389/fphys.2019.01399.
20. Yang HM, Kim J, Kim BK, Seo HJ, Kim JY, Lee JE, et al. Resistin Regulates Inflammation and Insulin Resistance in Humans via the En- docannabinoid System. Research. 2024;7:0326. DOI: https://doi.org/10.34133/research. 0326.
21. National Kidney Foundation. eGFR Calculator. New York: National Kidney Foundation. Available from: http://www.kidney.org/professionals/kdoqi/ gfr_calculator.cfm.
22.  Kreiner FF, Schytz PA, Heerspink HJL, von Scholten BJ, Idorn T. Obesity-Related Kidney Disease: Current Understanding and Future Perspectives. Biomedicines. 2023;11(9):2498. DOI: https://doi.org/10.3390/biomedicines 11092498.
23. Kounatidis D, Vallianou NG, Stratigou T, Voukali M, Karampela I, Dalamaga M. The Kidney in Obesity: Current Evidence, Perspectives and Controversies. Curr Obes Rep. 2024;13(4):680-702. DOI: https://doi.org/10.1007/s13679-024-00583-y.
24. Shaheen BA, Ziaur Rahman Z, Afzal M. Аssociation of circulating resistin levels with inflammatory markers, glycemic and lipid indi- ces in people with obesity, morbid obesity and lean pakistani subjects. Journal of Population Therapeutics and Clinical Pharmacology. 2024;31(5):434-446. DOI: https://doi.org/10.53555/jptcp.v31i5.6163.
25.  Liu G, Deng Y, Sun L, Ye X, Yao P, Hu Y, et al. Elevated plasma tumor necrosis factor-α receptor 2 and resistin are associated with increased incidence of kidney function decline in Chinese adults. Endocrine. 2016;52:541-549. DOI: 10.1007/s12020-015-0807-3.
26. Norman G, Woodiwiss AJ, Peterson V, Gomes M, Sareli P, Norton GR. Impact of metabolic and inflammatory changes on glomerular function beyond conventional risk factors in an urban South Africa community with prevalent obesity. Cardiovasc J Afr. 2020;31(4):91-102. DOI: 10.5830/CVJA-2019-057.
27. Asgary S, Samsamshariat SZA, Sakhaei F, Salehizadeh L, Keshvari M. Relationship between Resistin, Endothelin-1, and Flow-Mediated Dilation in Patient with and without Metabolic Syndrome. Adv Biomed Res. 2019;8:16. DOI: 10.4103/abr.abr_126_18.
28. Sun X, Qiu WW, Wu J, Ding SL, Wu RZ. Associations between the levels of circulating inflammatory adipokines and the risk of type 2 diabetes in Chinese male individuals: A case-control study. J Clin Lab Anal. 2023;37(6):e24875. DOI: 10.1002/jcla.24875.
29. Acquarone E, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: A reappraisal. Mech Ageing Dev. 2019;178:46-63. DOI: 10.1016/j.mad. 2019.01.004.
30. Su KZ, Li YR, Zhang D, Yuan JH, Zhang CS, Liu Y, et al. Relation of Circulating Resistin to Insulin Resistance in Type 2 Diabetes and Obesity: A Systematic Review and Meta-Analysis. Front Physiol. 2019;10:1399. DOI: 10.3389/fphys.2019.01399.
31. Alemán JO, Almandoz JP, Frias JP, Galindo RJ. Obesity among Latinx people in the United States: A review. Obesity (Silver Spring). 2023;31(2):329-337. DOI: 10.1002/oby.23638.
32. Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51-60. DOI: 10.1016/j.metabol.2018.11.009.
33.  Kadatane SP, Satariano M, Massey M, Mongan K, Raina R. The Role of Inflammation in CKD. Cells. 2023 Jun 7;12(12):1581.https://doi. org/10.3390/cells12121581

Publication of the article:

«Bulletin of problems biology and medicine», 2025 Issue 3,178, 136-145 pages, index UDC 612.398+616-002+616.008.9+616.61+616-056.52

DOI:

10.29254/2077-4214-2025-3-178-136-145